Methotrexate has spent decades quietly doing one job: calming the immune system in people with rheumatoid arthritis. Now researchers in South Australia have found it does something else entirely—and it might matter more for your long-term health than joint relief.
When people newly diagnosed with rheumatoid arthritis started methotrexate, their systolic blood pressure dropped by an average of 7.4 mmHg more than those taking sulfasalazine, another standard arthritis medication. That sounds modest. It's not. A reduction that size can meaningfully lower the risk of heart attacks and strokes—the kind of protection that compounds over years.
The finding matters because rheumatoid arthritis, which affects about 1 in 100 people, isn't just about painful joints. The disease creates persistent inflammation throughout the body, which damages blood vessels and the heart. People with RA face significantly higher cardiovascular disease rates than the general population. So any treatment that tackles both the arthritis and the underlying inflammation becomes genuinely valuable.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxHow they found it
Researchers at Flinders University and Southern Adelaide Local Health Network followed 62 adults who had just been diagnosed with RA and hadn't started treatment yet. Half received methotrexate, half got sulfasalazine. They measured blood pressure at the start, then at one month and six months, while also tracking joint inflammation and arterial stiffness.
Here's the interesting part: the blood pressure drop wasn't explained by better joint control or healthier arteries. The improvement seemed to work through separate biological pathways—possibly by reducing systemic inflammation or enhancing how blood vessels function. This suggests methotrexate's cardiovascular benefit operates independently from its anti-inflammatory effects on joints.
The team also looked for genetic patterns. They found that certain genetic variants predicted who would experience the biggest blood pressure drop on methotrexate. This opens a path toward personalized medicine: genetic testing could one day help doctors identify which patients would gain the most heart protection from this particular drug.
Lead researcher Professor Arduino Mangoni put it plainly: "Even a small drop in blood pressure can lower the risk of serious heart problems." That's not hype—it's epidemiology. Population studies consistently show that systolic blood pressure reductions in this range translate to measurable decreases in cardiovascular events over time.
What comes next
The findings are preliminary, and researchers emphasize that more work is needed to understand exactly how methotrexate lowers blood pressure and to confirm these results in larger groups. But the door is open to a broader understanding of how this decades-old drug works beyond the joints it was designed to treat. For the millions of people already taking methotrexate for arthritis, that unexpected heart benefit might be the most important side effect they never knew they were getting.
